October 20, 2023- To support emerging precision therapies and improve patient outcomes by increasing access to reliable genomic testing needed to match patients with targeted cancer treatments, Thermo Fisher Scientific announced a companion diagnostic (CDx) partnership with Boehringer Ingelheim. Through this collaboration, the companies will work to develop CDx tests to help identify patients with non-small cell lung cancer (NSCLC) with specific genomic mutations.
Lung cancer is one of the most common cancers, with 2.2 million cases worldwide in 2020 and is the leading cause of cancer death in both Japan and the U.S.The collaboration will leverage the Oncomine Dx Express Test on the Ion Torrent Genexus Dx System as well as the Oncomine Dx Target Test.
Boehringer Ingelheim has the aspiration to transform the lives of people with cancer by delivering meaningful advances, with the ultimate goal of curing a range of cancers. By partnering with Thermo Fisher, Boehringer Ingelheim aims to develop multiple companion diagnostic tests to ensure that labs using a variety of testing technologies will have the ability to match eligible patients with emerging NSCLC treatments as they become available.